TY - JOUR
AU - Okamoto, Masato
AB - ORIGINAL ARTICLE Clinical and Immunologic Evaluation of Dendritic CellYBased Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma Yukino Kimura, MS,* Jun Tsukada, PhD,*Þ Takeshi Tomoda, MD,þ Hidenori Takahashi, MD,þ Kazuhiro Imai, PhD,* Kanae Shimamura, MMS,* Makoto Sunamura, MD, PhD,§ Yoshikazu Yonemitsu, MD, PhD,|| Shigetaka Shimodaira, MD, PhD,¶ Shigeo Koido, MD, PhD,# Sadamu Homma, MD, PhD,þ** and Masato Okamoto, DDS, PhD*Þþ but do not yet exist in practice for PC. Therefore, surgical Objectives: In the current study, we have evaluated the clinical and resection (pancreaticoduodenectomy), which can be performed immunological responses in patients with advanced pancreatic carci- in only a small fraction of patients because of the generally ad- noma who received dendritic cell (DC)Ybased immunotherapy in com- vanced stage of the tumor at diagnosis, results in only a minimal bination with gemcitabine and/or S-1. 2 increase in survival. Even after resection, recurrence occurs in Methods: Dendritic cellYbased immunotherapy (DC vaccine alone most patients, leading to a median survival of approximately or DC vaccine plus lymphokine-activated killer [LAK] cell therapy) 18 months. Adjuvant treatment with both chemotherapy and ra- in combination with gemcitabine and/or S-1 has been carried out in diotherapy yields improvements in disease-free 
TI - Clinical and Immunologic Evaluation of Dendritic Cell–Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma
JF - Pancreas
DO - 10.1097/MPA.0b013e31822398c6
DA - 2012-03-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/clinical-and-immunologic-evaluation-of-dendritic-cell-ndash-based-bDpfX4w6vR
SP - 195–205-195&ndash
EP - ndash;205-195–205
VL - 41
IS - 2
DP - DeepDyve
ER -